Shares of Genomic Health Inc. (NASDAQ:GHDX) fell 5.1% on Tuesday . The company traded as low as $28.59 and last traded at $28.80, with a volume of 59,492 shares trading hands. The stock had previously closed at $30.34.

A number of brokerages have weighed in on GHDX. Canaccord Genuity upgraded shares of Genomic Health from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Wednesday, June 1st. Leerink Swann restated a “buy” rating on shares of Genomic Health in a research report on Thursday, May 26th. Finally, Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $33.50.

The stock’s market capitalization is $959.09 million. The firm has a 50-day moving average price of $27.07 and a 200 day moving average price of $26.78.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.18). During the same quarter in the previous year, the business earned ($0.29) earnings per share. The business earned $81.97 million during the quarter, compared to the consensus estimate of $81.27 million. The firm’s revenue was up 16.1% compared to the same quarter last year. On average, analysts expect that Genomic Health Inc. will post ($0.45) EPS for the current fiscal year.

In related news, COO G Bradley Cole sold 5,000 shares of the stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $27.60, for a total value of $138,000.00. Following the completion of the transaction, the chief operating officer now directly owns 39,970 shares in the company, valued at approximately $1,103,172. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Steven Shak sold 10,000 shares of the stock in a transaction dated Wednesday, May 4th. The stock was sold at an average price of $25.43, for a total transaction of $254,300.00. Following the completion of the transaction, the insider now owns 336,383 shares of the company’s stock, valued at $8,554,219.69. The disclosure for this sale can be found here.

A number of hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its stake in Genomic Health by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 32,989 shares of the company’s stock worth $1,161,000 after buying an additional 600 shares in the last quarter. ProShare Advisors LLC raised its stake in Genomic Health by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 28,759 shares of the company’s stock worth $1,012,000 after buying an additional 2,287 shares in the last quarter. Royce & Associates LLC raised its stake in Genomic Health by 90.0% in the fourth quarter. Royce & Associates LLC now owns 66,500 shares of the company’s stock worth $2,341,000 after buying an additional 31,500 shares in the last quarter. Russell Frank Co raised its stake in Genomic Health by 327.4% in the fourth quarter. Russell Frank Co now owns 99,754 shares of the company’s stock worth $3,517,000 after buying an additional 76,416 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Genomic Health during the fourth quarter worth $6,097,000.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.